Introduction

Purified populations of CD8
þ T cells from the lymph nodes and spleen of normal (unimmunized) C57BL/6 donor mice effectively kill lymphohematopoietic tumor cells in BALB/c hosts given lethal or sublethal total body irradiation (TBI) after addition to C57BL/6 T cell-depleted bone marrow (TCD BM) transplants, 1,2 but severe GVHD develops as the dose of purified CD8 þ T cells increases. 2 There is a narrow dose range of purified splenic CD8 þ T cells that effectively kills the BALB/c-derived BCL 1 lymphoma without inducing lethal GVHD. 1, 2 In contrast to splenic CD8 þ T cells, CD8 þ T cells purified from wild-type C57BL/6 donor bone marrow mediate the killing of BCL 1 tumor cells without inducing GVHD over a wide dose range. 1, 2 Tumor killing by CD8 þ T cells from the marrow was reduced or lost when perforin À/À or Fas ligand
) C57BL/6 mice were used as donors. 2 However, the relative contribution of alloantigen versus tumorspecific antigen recognition in the graft anti-tumor activity of donor splenic or marrow CD8 þ T cells has not been elucidated clearly in these major histocompatibility complex (MHC)-mismatched model systems using donors that are not immunized to the tumor antigens.
Zeng et al. 3 have documented previously the intriguing phenomenon that bone marrow-derived T cells differ significantly from peripheral T cells, not only in their surface receptor expression and cytokine secretion profiles but also in their ability to induce GVHD after MHC-mismatched allogeneic transplantation. Notably, at equal numbers, CD8 þ T cells derived from the blood but not the marrow induce lethal GVHD. Nevertheless, C57BL/6 marrow CD8 þ T cells maintained potent graft anti-tumor activity against BCL 1 , a BALB/c-derived lymphoma. 2, 3 However, the role of alloantigen versus tumor antigen recognition in graft anti-tumor activity of the marrow T cells is not clear, as the BCL 1 tumor expresses an immunogenic IgM-l idiotype tumor antigen. 4 BCL 1 tumor cells can be eliminated by the adoptive transfer of T cells from syngeneic hosts that have been immunized to the idiotype antigen. 5 A critical role for alloantigen recognition in CD8-mediated graft anti-tumor activity has been postulated by Reddy et al. 6 in an MHC-mismatched murine transplant setting in which MBL-2, a T cell lymphoma with an immunogenic tumor antigen, was used as the tumor model. In that study, when chimeric hosts with antigen-presenting cells (APCs) that failed to express class I MHC received transfer of sorted allogeneic donor splenic CD8 þ T cells, then neither GVHD nor anti-tumor immunity developed. In contrast, hosts with APCs that express Class I MHC developed both GVHD and anti-tumor activity. 6 The results indicate that MHC Class I host alloantigen expression on host APCs is required for graft anti-tumor activity. However, in this model the Class I host MHC may be required for presentation of tumor antigens as well as alloantigens to the donor CD8 þ T cells, since T cell tumors do not express the necessary co-stimulatory molecules expressed on APCs.
The objective of the current study was to use a deletional tolerance model and the BALB/c BCL 1 tumor to determine whether C57BL/6 bone marrow cells or C57BL/6 splenic CD8 þ T cells tolerized to BALB/c alloantigens can effectively eliminate the tumor in lethally irradiated BALB/c hosts with intact APCs.
Our results show that infusion of normal donor peripheral CD8
þ T cells eliminated residual normal and malignant host lymphohematopoietic cells and induced lethal GVHD. In contrast, C57BL/6 whole bone marrow cells eliminated the tumor cells in a CD8 T cell-dependent manner and did not induce lethal GVHD. However, the capacity to eliminate BCL 1 tumor cells was lost when whole bone marrow or splenic CD8 þ T cells were obtained from chimeric donors tolerized to host alloantigen, indicating a dependence of graft anti-tumor activity on alloantigen recognition rather than tumor antigen recognition. ) male donor mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). The Stanford University Committee on Animal Welfare (Administration Panel of Laboratory Animal Care) approved all mouse protocols used in this study.
Methods
Animals
Irradiation
Myeloablated recipients were given a single dose of lethal TBI, 800 cGy. The irradiation was performed with a Philips X-ray unit (200 kV, 10 mA; Philips Electronic Instruments Inc., Rahway, NJ, USA) at a rate of 84 cGy/min with a 0.5 mm Cu filter.
Cell preparation
Femoral and tibial bones taken from donor C57BL/6 mice were rinsed and the residual muscle on the bones carefully removed. Single-cell suspensions of bone marrow cells were prepared by flushing the bones with RPMI (Gibco BRL, Grand Island, NY, USA) with 2% of fetal bovine serum (FBS, Sigma Pharmaceuticals, Mountain View, CA, USA) and the cell suspension was filtered through nylon mesh to remove aggregates and resuspended in sterile PBS (Gibco BRL) before injection. To prepare TCD BM, whole C57BL/6 bone marrow cells were incubated with biotinylated anti-Thy1.2 mAb clone 5a-8 (Caltag, Burlingame, CA, USA), biotinylated anti-CD4 clone 3A-26.2, antiCD8a clone 53-6.7, and anti-TCRab clone H57-597 (Becton-Dickinson, San Diego, CA, USA) and then with streptavidin conjugated magnetic beads (Miltenyi Biotech, Friedrich, Germany). Cells were passed through a midi-MACS column (Miltenyi Biotech, Auburn, CA, USA) twice; the flow-through cells contained less than 0.5% TCRab þ cells as judged by subsequent immunofluorescent staining, and were used as TCD BM.
Flow cytometric analysis and fluorescence-activated cell sorting For chimerism and BCL 1 idiotype analysis, peripheral blood samples obtained from transplanted recipients were hemolyzed with ammonium chloride potassium carbonate (ACK) buffer to remove red cells. Splenocytes were hemolyzed with ACK buffer in sterile RPMI-1640 with 2% FBS. Cells were washed twice with 0.05% sodium azide staining buffer and incubated on ice for 20 min with saturating concentrations of monoclonal antibody mixtures as described previously. [1] [2] [3] All mouse cells were incubated with CD16/32 (2.4G2, Becton-Dickinson, San Diego, CA, USA) before antibody staining to block FcRg II/III receptors. The following conjugated mAbs were used: APC anti-TCRab clone H57-597, PE anti-Ly6C (Gr-1) clone RB6-8C5, PE anti-CD11b (Mac-1a) clone M1/70, biotin-anti-CD8 clone 53-6.7, PE anti-B220 clone RA3-6B2, FITC anti-H-2K b clone AF6-88.5 (Becton-Dickinson, San Diego, CA, USA), and Streptavidin -Texas Red (Molecular Probes, Eugene, OR, USA). FITC anti-BCL 1 idiotype was a gift from Dr R Levy, Stanford University. Propidium iodide was added before cytometric analysis to exclude dead cells. Samples were analyzed on a modified dual laser fluorescence-activated cell sorting (FACS) Vantage (Becton-Dickinson, Mountain View, CA, USA) in the Shared FACS Facility, Center for Molecular and Genetic Medicine at Stanford University, and data were analyzed using FlowJo software (TreeStar, Ashland, OR, USA).
Sorting of donor peripheral CD8 þ T cells was carried out by preparing single-cell suspensions of splenocytes from chimeric or wild-type C57BL/6 donors as above, enriching using anti-CD8-conjugated magnetic beads and the Midi MACS system (Miltenyi Biotech, Auburn, CA, USA), and sorting H-2K b þ CD8 þ TCRab þ cells using a Vantage dual-laser flow cytometer (Becton-Dickinson). Sorted populations were confirmed to be 498% pure by post-sort re-analysis.
Bone marrow and mononuclear cell infusion
In some experiments, single bone marrow cell suspensions from donors were injected via the lateral tail vein of recipients 24 h after irradiation. In other experiments, CD8
þ T cells from the donor spleen were prepared at a final dose concentration of 0.3 Â 10 6 in sterile PBS, and injected into irradiated hosts with 5 Â 10 6 TCD donor bone marrow cells. Some groups of recipients were given BCL 1 tumor cells at the time of donor cell transplantation. The dose of infused donor CD8 þ T cells in the whole bone marrow cell transplants was calculated to be between 0.2 and 0.3 Â 10 6 /mouse, approximating the dose of splenic CD8 þ T cells added to the TCD marrow transplants. Cell suspension volumes for each injection were adjusted to 0.5 ml to minimize variation of infused volumes and cell numbers.
Preparation of stable mixed chimeric donors BALB/c recipients were given a single dose of TBI, 800 cGy. Twenty-four hours following irradiation, recipients received 5 Â 10 6 C57BL/6 TCD BM intravenously via lateral tail vein injection. Recipients were assessed for donor-host chimerism at 28 and 100 days post transplant. These mice are referred to here as 'chimeras' or 'chimeric donors,' and cell populations derived from these donors that were transplanted into lethally irradiated secondary BALB/c hosts are referred to as 'chimeric' donor cells.
Carboxyfluoroscein succinimidyl ester mixed leukocyte reaction assay Stimulator cell splenocytes from C57BL/6, BALB/c and third-party C3H (H-2 k ) male mice were pooled from three animals per group, and irradiated with 3000 cGy using a Cesium source. Responder cells were splenocytes from normal C57BL/6 mice and C57BL/6-BALB/c chimeric mice. Responder cells from three mice were pooled in each experiment, with two experimental repeats. Responder cells were labeled with carboxyfluoroscein succinimidyl ester (CFSE) using the CellTrace CFSE assay system (Invitrogen Molecular Probes, Eugene, OR, USA) as per manufacturer's instructions. Responders were incubated with stimulators at a responder:stimulator (R:S) ratio of 1:1, in a 5% CO 2 incubator at 371C for 72 h. Cells were pooled from triplicate wells, stained with Cy7-PE conjugated anti-CD4 mAb (clone RM4-5) (E-Bioscience, San Diego, CA, USA), and biotin anti-H-2K b mAb (clone AF6-88.5) (Becton-Dickinson, San Diego, CA, USA), and Streptavidin -Texas Red. Cells were then analyzed using a modified FACS Vantage (Becton-Dickinson, Mountain View, CA, USA) with a 750 nm long-pass filter placed in the line of the 488 nm laser, in the Shared FACS Facility, Center for Molecular and Genetic Medicine at Stanford University, and data were analyzed using FlowJo software (TreeStar). Responder populations were gated on FlowJo for forward and orthogonal scatter, and the percentage of CFSE-high and CFSE-low cells was determined by histogram analysis on H-
Histopathology of liver, skin and intestine Animals were killed when moribund as per Stanford Animal Welfare protocol guidelines, or at 100 days after transplantation if they survived without morbidity. Histopathological specimens were obtained at the time of killing from the skin, spleen, liver, small and large intestines of all hosts. Tissues were fixed in 10% formalin, embedded in paraffin blocks, and 4-to 5-mm sections were stained with hematoxylin and eosin using standard protocols. [1] [2] [3] Microscopic images were obtained using an Eclipse E1000M microscope (Nikon, Melville, NY, USA) with SPOT RT digital camera and acquisition software (Diagnostic Instruments, Sterling Heights, MI, USA) with final magnification (objective, Â 20/0.45 numerical aperture) provided with each figure. Image processing was performed with Photoshop CS (Abode Systems, San Jose, CA, USA) with standard adjustments of brightness, contrast and color balance to the entire image.
Pathologic scoring for GVHD severity At the time of histopathologic analysis of hematoxylin/ eosin-stained sections, the descending colon, skin and liver were assigned a score assessing severity of GVHD as per previously published criteria. 7 The mean GVHD score represents the mean7s.e.m. among 5-8 animals per group.
Analysis of splenic V b subsets
At day 28, single-cell suspensions were prepared from spleens of transplanted chimeras or wild-type C57BL/6 or BALB/c controls. Cells were stained with APC anti-CD8 clone 53-6.7, PE anti CD3 and biotin anti-H-2K b clone AF6-88.5 (BectonDickinson, San Diego, CA, USA) with secondary streptavidinTexas Red (Molecular Probes), and FITC anti-V b subsets, 2, 3, 5.1 and 5.2, 6, 8, 9, 10, 11 and 12 as per previous publications. 8, 9 Statistical comparison was made between the mean percentage of each V b subset among splenic CD3 þ CD8 À cells of control C57BL/6 and BALB/c mice versus the H-
À splenocytes of chimeric mice. Means and standard deviations were calculated for two experiments, with a total of five animals in each group. BCL 1 tumor cell passage and injection BCL 1 is a B-cell leukemia/lymphoma derived from BALB/c mice expressing a tumor-specific IgM-l surface Ig. 4, 10 This cell line was maintained in vivo by serial passage in wildtype BALB/c mice as described previously. [10] [11] [12] [13] [14] [15] [16] A dose of 5 Â 10 2 BCL 1 cells from spleen of tumor-laden BALB/c mice was injected intravenously into transplanted BALB/c hosts and non-transplanted, sublethally irradiated or nonirradiated BALB/c controls.
Statistical analysis
Kaplan-Meier survival curves were generated using Prism software (SAS Institute Inc., Cary, NC, USA), and statistical differences were analyzed using the log-rank (Mantel-Cox) test. Statistical significance in differences between mean percentage of each donor V b subset of the T-cell repertoire and statistical significance in differences between mean histopathologic GVHD scores were analyzed using the two-tailed Student's t-test of means. For all tests, Po0.05 was considered significant.
Results
Mixed donor T cell chimerism in spleen and full donor T cell chimerism in the bone marrow of mice used as source of tolerant donor cells To assess the effect of tolerance to host alloantigen on the anti-tumor activity of donor CD8 þ T cells, we generated chimeras in which donor T cells were rendered tolerant to host MHC and minor alloantigens. BALB/c mice were treated with 800 cGy TBI and infused with 5 Â 10 6 T celldepleted wild-type C57BL/6 bone marrow cells to create C57BL/6-BALB/c stable mixed T cell chimeras (herein called 'chimeras'). b þ cells was also not statistically different from those in bone marrow of untreated C57BL/6 donors (0.870.2% for CD8 and 0.470.05% for CD4, respectively) in our study or in previous reports. 3 Chimeras were used at day 28 after transplantation as donors of pooled whole bone marrow cells or sorted splenic 
Allorecognition in CD8 T-cell anti-tumor activity
A Pillai et al from C57BL/6, BALB/c and third-party C3H (H-2 k ) male mice. Responder cells were splenocytes from either normal C57BL/6 or C57BL/6-BALB/c chimeric animals. As shown in Figure 1c , the gated H-2K b þ CD4 þ responder cells from chimeric mice showed little cell division using C57BL/6 and BALB/c stimulator cells as judged by minimal reduction in CFSE staining intensity. In contrast, there was vigorous cell division using third-party C3H stimulators. As shown in Figure 1d, Splenocytes from chimeras display clonal deletion of T cell receptor V b subsets specific for BALB/c superantigens We assessed clonal deletion of TCR subsets as one parameter of allotolerance of transplanted C57BL/6 cells in the C57BL/6-BALB/c chimeras described. Normal C57BL/6 and BALB/c mice differ in their V b receptor repertoire among CD4 þ T cells, since the I-E antigenpresenting molecule is expressed by the latter but not the former strain. 8 This results in the superantigen-induced clonal deletion of several V b receptor subsets in BALB/c but not C57BL/6 mice during thymic negative selection. 8, 9 Spleens of chimeras were stained for donor MHC H-2K b , CD3, and CD8 and the V b subsets, 2, 3, 5.1 and 5.2, 6, 8, 9, 10, 11 and 12. Statistical comparison was made between the mean percentages of each V b subset among the gated
cells in chimeras and the CD3
þ CD8 À cells of C57BL/6 and BALB/c controls (Table 1) . Chimeras had o1%
À cells. The latter percentages were significantly reduced (Po0.05) in comparison to those of normal C57BL/6 mice. The P-values for comparison of the means between C57BL/6 and BALB/c mice were also significant (Po0.05) for the same subsets (Table 1) , and were not significant between chimeras and BALB/c mice (P40.10). There were no significant differences in the percentages of T cells expressing V (Figure 2a) . At autopsy after 100 days, there was no histopathologic evidence of GVHD in skin, colon or liver in hosts receiving TCD BM, normal BM or chimeric BM (data not shown). In particular, the skin showed no evidence of epidermal hyperplasia or dermal infiltrates, the colon showed normal crypt architecture and intact goblet cells, and the liver showed minimal inflammation of the portal triads. The mean histopathologic GVHD scores for mice receiving TCD BM were 0.570.2 for liver, 1.170.1 for colon and 1.370.2 for skin (Figure 2b ), and were not significantly different from those of mice receiving normal or chimeric BM (P ¼ 0.08 for TCD BM versus normal BM; P ¼ 0.18 for TCD BM versus chimeric BM; and P ¼ 0.07 for normal BM versus chimeric BM). 
Allorecognition in CD8 T-cell anti-tumor activity A Pillai et al
Normal C57BL/6 marrow transplants eliminated BCL 1 tumor but tolerized chimeric marrow transplants did not Our previous studies showed that donor CD8 þ T cells in C57BL/6 whole bone marrow were able to eliminate the BALB/c-derived BCL 1 B cell lymphoma in BALB/c hosts, and that TCD BM and CD8 T cell-knockout bone marrow cells (CD8 À/À BM) from C57BL/6 donors lost tumorelimination capacity.
1,2 Here we compared the efficacy of BCL 1 tumor elimination by wild type and CD8 À/À C57BL/ 6 whole bone marrow transplants, C57BL/6 TCD bone marrow transplants and transplants of marrow from C57BL/6-BALB/c chimeras. We administered 800 cGy TBI to BALB/c hosts and injected 5 Â 10 2 BCL 1 lymphoma cells at day 0 with 50 Â 10 6 BM cells from the different donors. All hosts given TCD BM, CD8 À/À BM or chimeric BM cells died by day 100, but hosts given normal BM cells survived at least 100 days ( Figure 2c ). All groups autopsied after 100 days showed no histopathologic evidence of GVHD in skin, colon and liver (data not shown). The groups given TCD BM, CD8 À/À BM or chimeric BM had clear histologic evidence of monomorphic tumor cells in the spleen at autopsy (Figure 3a) .
In these groups, there was also clear immunophenotypic evidence of BCL 1 idiotype-positive cells in peripheral blood by immunofluorescent staining on day 28 (Figure 3b ). All hosts in these groups had at least 10% of blood mononuclear cells that stained positively for the idiotype tumor cell marker as judged by one-color cytometric analysis (Figure 3b) . By contrast, injection of 5 Â 10 2 BCL 1 B-cell lymphoma cells simultaneous with 50 Â 10 6 normal C57BL/6 BM cells resulted in no histopathologic evidence of tumor in spleen at 100 days post-transplant (Figure 3a, third row) . Nine of 10 of these animals had less than 1% BCL 1 idiotypepositive cells in peripheral blood at day 28 (Figure 3b , third row). The results show that prevention of progressive growth of the BCL 1 tumor by C57BL/6 marrow transplants is dependent on marrow CD8 þ T cells, and this anti-tumor activity is lost using chimeric donor marrow cells. (Figure 4a) . Histopathologic analysis of the colon (Figure 5a, second row) showed that the intestinal crypts were depleted of plump mucin containing glandular cells, and a lymphocytic infiltrate was observed surrounding the crypts (asterisks), accompanied by apoptotic crypt lining cells (arrows). Characteristic GVHD skin lesions were observed, including lymphocytic dermal infiltrate and epidermal necrosis and blistering (data not shown). In the liver, an intense periportal lymphocytic infiltrate was also seen (data not shown). The spleens in these animals revealed splenitis with an inflammatory neutrophilic infiltrate and depletion of the white pulp (Figure 5a mean histopathologic GVHD scores for mice receiving TCD BM with normal C57BL/6 CD8 T cells were 3.170.2 for liver, 7.170.2 for colon and 5.570.3 for skin, whereas those for mice receiving TCD BM with chimeric CD8 T cells were 0.670.2 for liver, 1.570.3 for colon and 1.770.5 for skin (Figure 4b ). The differences in mean GVHD scores between these two groups were statistically significant (P ¼ 0.04 by two-tailed Student's t-test). By contrast, the mean GVHD scores between mice given TCD BM alone versus those given chimeric CD8 T cells with TCD BM were not significantly different (P ¼ 0.51). in survival between these two groups of hosts was not statistically significant (P ¼ 0.32). Hosts given sorted normal CD8 þ T cells had characteristic clinical features of GVHD including weight loss, hunched back and loss of fur. In colon sections taken from the group given sorted normal splenic H- (Figure 5a , fourth row), the intestinal crypts were depleted of plump mucin containing glandular cells, and a lymphocytic infiltrate was observed surrounding the crypts (asterisks), accompanied by apoptotic crypt lining cells (arrows).
In skin sections for mice receiving BCL 1 and normal splenic H-2K b þ CD8 þ TCRab þ cells, characteristic microscopic GVHD lesions were observed, including lymphocytic dermal infiltrates and epidermal necrosis and blistering (data not shown). In liver sections, an intense periportal lymphocytic infiltrate was seen (data not shown). There was no histologic evidence of tumor in the spleen at the day of autopsy, and there was splenitis with an inflammatory neutrophilic infiltrate and depletion of the white pulp (Figure 5a, fourth row) . In this group, there was no evidence of BCL 1 idiotype in peripheral blood at day 28, and BCL 1 idiotype-positive cells were less than 1% of PBMC in all hosts (Figure 5b, fourth row) . Histopathologic monitoring of hosts given sorted chimeric H-2K b þ CD8 þ TCRab þ cells revealed no evidence of GVHD in colon (Figure 5a, fifth row) , skin or liver (data not shown). There was clear evidence of diffuse tumor infiltration of the spleen with loss of splenic architecture (Figure 5a, fifth row) . In addition, there was immunophenotypic evidence of BCL 1 tumor in peripheral blood at day 28 with at least 10% of idiotype-positive cells among PBMCs of all hosts (Figure 5b, fifth row) .
Discussion
In the current study, we compared the ability of bone marrow and sorted splenic CD8 þ T cells from normal C57BL/6 donors and from chimeric (C57BL/6-BALB/c) donors to induce GVHD and to eliminate the BCL 1 tumor. We created C57BL/6-BALB/c stable mixed chimeras using lethal irradiation in BALB/c hosts followed by infusion of TCD BM from normal C57BL/6 donors. The goal was to establish an in vivo system in which donor T cells maintained allo-specific tolerance. We have previously demonstrated that the donor cell tolerance achieved in C57BL/6-BALB/c stable chimeras is specific to host alloantigens. 17, 18 BALB/c mice given allogeneic (C57BL/6) bone marrow cells after lymphoid irradiation become stable chimeras with approximately 80% donor-type and 20% host-type cells in the spleen. 17, 18 The levels of donor chimerism closely mimicked those in the current study. Purified donor cells of C57BL/6 origin from the chimeras mediated GVHD in irradiated C3H (third party), but not in irradiated BALB/c (host-strain) mice. 18 Thus the loss of GVHD inducing activity of donor T cells in these stable mixed chimeras was donor specific and not attributable to global immunodeficiency or immunosuppression of transplanted hosts.
We have previously demonstrated that C57BL/6 T cells in stable mixed chimeras that are tolerant to BALB/c heart allografts exhibit clonal deletion of BALB/c superantigenspecific subsets. 19 Other studies of mixed chimeras using non-myeloablative regimens have shown that negative selection of host T cells is due to the presence of donorderived dendritic cells in the host thymus. 20 The clonal deletion pattern of the donor V b T-cell subsets observed herein indicates that the C57BL/6 (H-2 b ) donor cells have been negatively selected to host (H-2 d ) MHC antigens. In addition, the specific reduction in BALB/c alloreactivity by chimeric donor-type CD4 T cells in the CFSE MLR assay relative to normal C57BL/6 donor CD4
þ T cells provides evidence that the sorted chimeric T cells used in this study were specifically allotolerant to host antigens and not globally suppressed or immunodeficient. It is theoretically possible that clonal deletion could additionally result in the deletion of donor T-cell V b receptor subsets that were reactive against immunogenic tumor-specific antigens on the BCL 1 tumor cells. However, in previous studies demonstrating the syngeneic anti-tumor response against 
donors. Survival curves represent the sum of three similar experiments, with a total of 13-15 hosts in each group. BCL 1 lymphoma, there has been no evidence that antitumor activity is dependent on any particular V b subset pattern. 5 Lethally irradiated BALB/c hosts given T cell-replete and T cell-depleted normal C57BL/6 marrow cells and BCL 1 tumor cells showed similar minimal microscopic GVHD in the skin, colon or liver, and tumor cells were eliminated using T-cell replete transplants. This is not surprising, since previous studies have shown that injection of MHCmismatched bone marrow cells, with minimal blood contamination, failed to induce severe GVHD and yet eradicated BCL 1 tumor cells in sublethally irradiated hosts. [1] [2] [3] 21 It is possible, however, that our histopathologic assessment of 100-day survivors could miss transient mild GVHD in the first month after transplantation, when animal weight was the main feature used to assess GVHD.
Transplantation with CD8
À/À C57BL/6 marrow or TCD C57BL/6 marrow resulted in loss of graft anti-tumor activity, indicating a critical role for donor CD8 þ T cells. hosts with clinical and microscopic evidence of GVHD and no histopathologic evidence of tumor progression. In addition, 90% of these transplanted hosts showed no evidence of microscopic residual tumor by day 28 immunophenotyping of peripheral blood for BCL 1 tumor idiotype. Therefore, alloreactive spleen-derived normal C57BL/6 CD8 þ TCRab þ cells both cleared BCL 1 tumor and induced GVHD in our study.
However, when normal C57BL/6 TCD BM cells and BCL 1 tumor cells were transplanted with sorted splenic H-2K b þ CD8 þ TCRab þ cells from chimeric donors that were tolerant of host alloantigen, all hosts succumbed to BCL 1 tumor progression without microscopic evidence of GVHD. Given that BCL 1 tumor idiotype antigen has been shown previously to be immunogenic in transplantation models, 5 the simultaneous loss of host alloreactivity (evidenced by lack of GVHD) with loss of graft anti-tumor activity (evidenced by uniform tumor progression) suggests that host alloantigen recognition by peripheral donor CD8 T cells is critical for maintenance of their anti-tumor activity. Thus, we have demonstrated, using both marrow CD8 T cells (in whole marrow transplants) and peripheral CD8 T cells (using sorted splenic CD8 T cells added to TCD BM cells), that donor CD8 T cells tolerized to host alloantigens lose their capacity to eliminate the BCL 1 lymphoma, a host MHC-expressing tumor.
In this study, we have not examined the effect of dose escalation of allotolerized CD8 T cells or dose de-escalation of tumor on anti-tumor activity; hence, we do not address the question of whether the loss of anti-tumor activity in chimeric CD8 T cells is partial or complete. Further studies could examine whether graft anti-tumor activity is lost by allotolerant donor CD8 T cells across a different MHCmismatched strain combination, or using a different tumor to examine tumor-specific artifacts. Though our study provides substantive evidence for the dependence of CD8 T cell-mediated graft anti-tumor activity on alloantigen recognition, it is possible that the loss of anti-tumor activity using tolerant donor cell transplants in our study could be due to the loss of an 'immune adjuvant' effect of GVHD that can facilitate the immune response to specific tumor antigens. Previous studies have used a parent-into-F1 transplant model, in which the tumor is syngeneic with the parent, to identify this effect, 22 and this would be a relevant area for further study in our model.
Our transplants of equal numbers of bone marrow cells from chimeric and normal donors contained similar numbers of CD8 T cells, as chimeras did not differ from normal C57BL/6 donors in their percentage of H-2K b þ cells among total T cells, or in their percentage of total T cells. In the study by Ciavarra et al. 5 demonstrating syngeneic anti-tumor response against BCL 1 tumor, the total effector splenocyte dose of 50 Â 10 6 cells would have provided an estimated CD8 T-cell dose of 4-5 Â 10 6 cells/ mouse. Although this dose of cells is about ten-fold higher than the dose of CD8 þ T cells from marrow or spleen used in the current study, the latter study did not determine the minimum dose of syngeneic splenocytes required to achieve tumor eradication. The allogeneic splenic CD8 þ T-cell dose used in our study was similar to those used in previous studies investigating BCL 1 tumor clearance using marrowderived CD8 þ T-cell populations. 1, 2 The potential role of other marrow-derived cell populations in graft anti-tumor activity and the effect of allotolerization on function of those populations is not addressed in our experiments.
A critical role for alloantigen recognition in graft antitumor activity following myeloablative bone marrow transplantation has been described previously by others. 6, 23 Reddy et al. 6 used hosts with APCs that did not express class I MHC antigens, and found that allogeneic transplants were unable to clear a variety of clinically relevant hematolymphoid tumors. 6 However, lack of graft antitumor activity could be due to a failure of these APCs to present tumor antigens as well as host alloantigens to donor T cells. The recognition of tumor-associated antigens in graft anti-tumor activity has been documented in a recent report using parent-F 1 BM transplants in which donor CD8 þ T-cell effectors eliminated donor-derived tumors in the hosts, and these effectors maintained anti-tumor activity in secondary transfers to donor strain hosts. 22 However, these tumor-specific responses were clearly dependent on donor T-cell recognition of MHC alloantigens on host cells and the subsequent development of GVHD. 23 In the current report, we further point out that bone marrow T cells from normal donors can eliminate the BCL 1 tumor in the absence of GVHD.
We conclude that graft anti-tumor activity mediated by CD8 þ T cells from unimmunized donors against BCL 1 B-cell lymphoma requires host alloantigen recognition following MHC-mismatched myeloablative bone marrow transplantation.
